Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
- 1 January 2008
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 100 (08), 217-223
- https://doi.org/10.1160/th08-02-0117
Abstract
Evaluation of factor F(V)III replacement in patients with haemophilia A undergoing surgery is critical for FVIII concentrates, yet large scale, multi-center prospective studies, particularly using continuous infusion, are generally lacking for new products. This study evaluated efficacy and safety of a newly developed recombinant FVIII (rAHF-PFM) administered by bolus or continuous infusion in haemophilia A patients undergoing surgery. Subjects ≥5 years of age with baseline FVIII:C ≤2%, and ≥150 prior FVIII exposure days were included in this prospective, international, open-label, uncontrolled clinical trial. rAHFPFM was administered perioperatively by bolus infusion (BI) or continuous infusion (CI) according to the standard use at the center to prevent bleeding complication. Both the surgeon and haematologist rated efficacy during hospitalization. Fifty-eight subjects underwent 65 surgical procedures (22 major haemor rhagic risk; 35 minor, 8 dental procedures). Bolus infusion was used exclusively in 47 procedures and continuous infusion, with or without supplemental bolus infusions, in 18.Haemostatic efficacy was assessed as excellent or good for 100% of intraoperative ratings (17 CI, 44 BI, 61 total procedures), and 100% of postoperative ratings performed at time of discharge (18 CI, 44 BI, 62 total procedures). Median total consumption of rAHF-PFM during hospitalization was 822 IU/kg/surgery with CI and 910 IU/kg/surgery with BI. Overall rAHF-PFM was well tolerated, and FVIII inhibitors were not detected. In conclusion, rAHF-PFM administered via continuous infusion or bolus injections is safe, non-immunogenic, and effective for perioperative hemostatic management in previously treated haemophilia A patients.This publication has 24 references indexed in Scilit:
- Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusionBlood Coagulation & Fibrinolysis, 2006
- Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A1Haemophilia, 2004
- Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method: Proceedings of a special symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12–18, 2003, Birmingham, UKSeminars in Hematology, 2004
- Continuous infusionHaemophilia, 2003
- Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma‐derived or recombinant factor VIII concentratesHaemophilia, 2002
- Continuous infusion of coagulation factorsHaemophilia, 2002
- High titre inhibitor after continuous factor VIII administration for surgery in a young infantHaemophilia, 2000
- Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience.Australian and New Zealand Journal of Medicine, 1998
- The use of continuous infusion of factor concentrates in the treatment of hemophiliaAmerican Journal of Hematology, 1989
- Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia AAmerican Journal of Hematology, 1984